Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and S-1 Second-line Treatment in Advanced Hepatocellular Carcinoma
ChiCTR-OPC-16008637Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Rivoceranib and tegafur in hepatocellular carcinoma (HCC) (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: overall survival. Started Jun 2016; status: recruiting.
02
Drugs
Rivoceranibtegafur
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-OPC-16008637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16008637.